- Home
- IFRX vs VANI Comparison
IFRX vs VANI Comparison
Compare IFRX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- VANI
- Stock Information
- Founded
- IFRX 2007
- VANI 1998
- Country
- IFRX Germany
- VANI United States
- Employees
- IFRX N/A
- VANI N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IFRX Health Care
- VANI Health Care
- Exchange
- IFRX Nasdaq
- VANI Nasdaq
- Market Cap
- IFRX 120.1M
- VANI N/A
- IPO Year
- IFRX 2017
- VANI 2014
- Fundamental
- Price
- IFRX $2.06
- VANI $1.33
- Analyst Decision
- IFRX Strong Buy
- VANI Strong Buy
- Analyst Count
- IFRX 1
- VANI 1
- Target Price
- IFRX $8.00
- VANI $3.00
- AVG Volume (30 Days)
- IFRX 266.7K
- VANI 131.4K
- Earning Date
- IFRX 11-08-2024
- VANI 11-13-2024
- Dividend Yield
- IFRX N/A
- VANI N/A
- EPS Growth
- IFRX N/A
- VANI N/A
- EPS
- IFRX N/A
- VANI N/A
- Revenue
- IFRX $187,930.00
- VANI N/A
- Revenue This Year
- IFRX $311.47
- VANI N/A
- Revenue Next Year
- IFRX $227.11
- VANI N/A
- P/E Ratio
- IFRX N/A
- VANI N/A
- Revenue Growth
- IFRX 177.12
- VANI N/A
- 52 Week Low
- IFRX $1.17
- VANI $0.84
- 52 Week High
- IFRX $2.44
- VANI $7.80
- Technical
- Relative Strength Index (RSI)
- IFRX 67.23
- VANI 55.69
- Support Level
- IFRX $1.51
- VANI $1.23
- Resistance Level
- IFRX $2.15
- VANI $1.34
- Average True Range (ATR)
- IFRX 0.24
- VANI 0.07
- MACD
- IFRX 0.05
- VANI -0.00
- Stochastic Oscillator
- IFRX 60.42
- VANI 46.15
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.